Vitamin D3 for Life

Live Enlightened

Research libraryVitamin D3 For Life
Study design and methods

Secondary relevance to vitamin D This paper mainly addresses another topic and also reports a vitamin D analysis, result or scientific synthesis.

This paper mainly addresses another topic and also reports a vitamin D analysis, result or scientific synthesis.

Why this paper is included

Supporting source evidence:

Moreover, the serum PTH and 1,25(OH)2D3 levels were significantly decreased by 39.86% ± 9.72% and 39.87% ± 8.55%, respectively, in Bbx−/− mice (Fig. 3k, l).

Source: Hypophosphatemia and increased serum FGF23 levels in Bbx-deficient mice. View original paper

Relevance classification does not establish study quality, causation or editorial approval.

Study design Study design awaiting verification.

Study design awaiting verification

The available source does not establish a sufficiently clear study design.

Meta-analysis unclear · Blinding unclear / not reported · Animal research reported

How this paper was classified

Automatic source-based classification; awaiting editorial verification. This is not a quality score.

Bbx−/− mice were generated by breeding the EUCOMM mouse strain C57BL/6N-Bbxtm1a (EUCOMM)Wtsi/+ (Wellcome Sanger Institute, Hinxton, Cambridgeshire, UK) with the Flp recombinase and protamine-Cre transgenic mouse strains, as described previously.

Source: Methods.

View supporting evidence in the original paper

What the study types mean
Systematic review
Uses explicit methods to identify, assess and summarise research on a defined question.
Scoping review
Maps the extent and characteristics of research on a topic.
Narrative review
Discusses existing research; systematic-review methods have not been established by this classification.
Review / evidence synthesis
Reviews existing research; the exact review methods need further assessment.
Randomised controlled trial
Assigns participants or groups to comparison interventions by chance.
Non-randomised intervention study
Examines an intervention without random allocation.
Cohort study
Examines exposures and outcomes over time within a defined group.
Case-control study
Compares people with an outcome against people without it, examining exposures.
Cross-sectional study
Examines a population at a particular point in time.
Observational study
Observes exposures and outcomes without assigning the exposure; the subtype is not established here.
Case report
Describes an individual case.
Case series
Describes a group of individual cases.
Secondary analysis
Analyses existing study data; this paper is not automatically another independent trial.
Laboratory study
Investigates biological processes in a laboratory setting.
Qualitative study
Examines experiences or meanings using qualitative methods.
Genetic instrumental-variable study
Uses genetic variation as an instrument to investigate relationships; this is not a randomised treatment trial.
Study protocol
Describes planned methods and is not evidence that the planned study has reported results.
Multiple reported designs
More than one design is explicitly reported; examine the supporting methods.
Study design awaiting verification
The available source does not establish a sufficiently clear study design.

Meta-analysis combines numerical results from studies. Blinding describes who was unaware of treatment allocation. Neither is a separate quality grade. Study design, vitamin D relevance and document format are independent filters.

Abstracts

The transcription factor BBX regulates phosphate homeostasis through the modulation of FGF23

Study design awaiting verification · Experimental & Molecular Medicine · 2024

Original publication title

The transcription factor BBX regulates phosphate homeostasis through the modulation of FGF23

Su Jeong Lee; Ju Ang Kim; Hye Jung Ihn; Je-Yong Choi; Tae-Yub Kwon; Hong-In Shin; Eui-Sic Cho; Yong Chul Bae; Rulang Jiang; Jung-Eun Kim; Eui Kyun Park

© The Author(s) 2024

Original publication · Publisher record · CC BY 4.0

Source wording retained. Formatting, section navigation and display-title punctuation adapted for this research record.

At a glance

What does the authors’ abstract report?

Fibroblast growth factor 23 (FGF23) plays an important role in phosphate homeostasis, and increased FGF23 levels result in hypophosphatemia; however, the molecular mechanism underlying increased FGF23 expression has not been fully elucidated. In this study, we found that mice lacking the bobby sox homolog (Bbx−/−) presented increased FGF23 expression and low phosphate levels in the serum and skeletal abnormalities such as a low bone mineral density (BMD) and bone volume (BV), as well as short and weak bones associated with low bone formation.

Osteocyte-specific deletion of Bbx using Dmp-1-Cre resulted in similar skeletal abnormalities, elevated serum FGF23 levels, and reduced serum phosphate levels. In Bbx−/− mice, the expression of sodium phosphate cotransporter 2a (Npt2a) and Npt2c in the kidney and Npt2b in the small intestine, which are negatively regulated by FGF23, was downregulated, leading to phosphate excretion/wasting and malabsorption. An in vitro Fgf23 promoter analysis revealed that 1,25-dihydroxyvitamin D3 (1,25(OH)2D3)-induced transactivation of the Fgf23 promoter was significantly inhibited by BBX overexpression, whereas it was increased following Bbx knockdown.

Interestingly, 1,25(OH)2D3 induced an interaction of the 1,25(OH)2D3 receptor (VDR) with BBX and downregulated BBX protein levels. Cycloheximide (CHX) only partially downregulated BBX protein levels, indicating that 1,25(OH)2D3 regulates BBX protein stability. Furthermore, the ubiquitination of BBX followed by proteasomal degradation was required for the increase in Fgf23 expression induced by 1,25(OH)2D3. Collectively, our data demonstrate that BBX negatively regulates Fgf23 expression, and consequently, the ubiquitin-dependent proteasomal degradation of BBX is required for FGF23 expression, thereby regulating phosphate homeostasis and bone development in mice.

BBX degradation drives FGF23 expression and compromises bone health

Phosphate, a vital component for various bodily functions, is regulated by a complex system involving hormones like FGF23. Researchers investigated how the absence of a gene called Bobby sox homolog (BBX) impacts phosphate balance and bone health. Researchers created BBX-deficient mice, and measured various factors, including bone mineral density and strength, as well as the impact of BBX on phosphate-regulating hormones. They found that lack of BBX in mice leads to lower phosphate levels, weaker bones, and increased FGF23 levels, disrupting phosphate balance.

Additionally, they discovered that an active form of vitamin D3 lowers BBX levels through a process called ubiquitin-dependent proteasomal degradation, which is important for controlling FGF23. The study concluded that BBX deficiency causes significant bone weakness and disrupts phosphate levels by increasing FGF23. This summary was initially drafted using artificial intelligence, then revised and fact-checked by the author.

Authors’ abstract

Fibroblast growth factor 23 (FGF23) plays an important role in phosphate homeostasis, and increased FGF23 levels result in hypophosphatemia; however, the molecular mechanism underlying increased FGF23 expression has not been fully elucidated. In this study, we found that mice lacking the bobby sox homolog (Bbx−/−) presented increased FGF23 expression and low phosphate levels in the serum and skeletal abnormalities such as a low bone mineral density (BMD) and bone volume (BV), as well as short and weak bones associated with low bone formation.

Osteocyte-specific deletion of Bbx using Dmp-1-Cre resulted in similar skeletal abnormalities, elevated serum FGF23 levels, and reduced serum phosphate levels. In Bbx−/− mice, the expression of sodium phosphate cotransporter 2a (Npt2a) and Npt2c in the kidney and Npt2b in the small intestine, which are negatively regulated by FGF23, was downregulated, leading to phosphate excretion/wasting and malabsorption. An in vitro Fgf23 promoter analysis revealed that 1,25-dihydroxyvitamin D3 (1,25(OH)2D3)-induced transactivation of the Fgf23 promoter was significantly inhibited by BBX overexpression, whereas it was increased following Bbx knockdown.

Interestingly, 1,25(OH)2D3 induced an interaction of the 1,25(OH)2D3 receptor (VDR) with BBX and downregulated BBX protein levels. Cycloheximide (CHX) only partially downregulated BBX protein levels, indicating that 1,25(OH)2D3 regulates BBX protein stability. Furthermore, the ubiquitination of BBX followed by proteasomal degradation was required for the increase in Fgf23 expression induced by 1,25(OH)2D3. Collectively, our data demonstrate that BBX negatively regulates Fgf23 expression, and consequently, the ubiquitin-dependent proteasomal degradation of BBX is required for FGF23 expression, thereby regulating phosphate homeostasis and bone development in mice.

BBX degradation drives FGF23 expression and compromises bone health

Phosphate, a vital component for various bodily functions, is regulated by a complex system involving hormones like FGF23. Researchers investigated how the absence of a gene called Bobby sox homolog (BBX) impacts phosphate balance and bone health. Researchers created BBX-deficient mice, and measured various factors, including bone mineral density and strength, as well as the impact of BBX on phosphate-regulating hormones. They found that lack of BBX in mice leads to lower phosphate levels, weaker bones, and increased FGF23 levels, disrupting phosphate balance.

Additionally, they discovered that an active form of vitamin D3 lowers BBX levels through a process called ubiquitin-dependent proteasomal degradation, which is important for controlling FGF23. The study concluded that BBX deficiency causes significant bone weakness and disrupts phosphate levels by increasing FGF23. This summary was initially drafted using artificial intelligence, then revised and fact-checked by the author.

Publication and source details

Original title: The transcription factor BBX regulates phosphate homeostasis through the modulation of FGF23

Su Jeong Lee; Ju Ang Kim; Hye Jung Ihn; Je-Yong Choi; Tae-Yub Kwon; Hong-In Shin; Eui-Sic Cho; Yong Chul Bae; Rulang Jiang; Jung-Eun Kim; Eui Kyun Park

Experimental & Molecular Medicine · 2024

© The Author(s) 20242024https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.https://doi.org/10.13039/501100003725National Research Foundation of Korea (NRF)2017R1A5A20153912017R1A2B4003612RS-2023-00241950Park Eui Kyun

Repository JATS snapshot; version as supplied

Source retrieved: 2026-11-11T03:22:42.269963+00:00

DOI: 10.1038/s12276-024-01341-9 · PMC11612488